Research trends in cholangiocarcinoma treatments during the last 3 decades

[1]  Qiu-na Xu,et al.  Development and validation of an XGBoost model to predict 5-year survival in elderly patients with intrahepatic cholangiocarcinoma after surgery: a SEER-based study , 2022, Journal of gastrointestinal oncology.

[2]  Mingyu Chen,et al.  Identification of Publication Characteristics and Research Trends in the Management of Gallbladder Cancer , 2022, iLIVER.

[3]  S. Maithel,et al.  NEO-GAP: A phase II single-arm prospective feasibility study of neoadjuvant gemcitabine/cisplatin/nab-paclitaxel for resectable high-risk intrahepatic cholangiocarcinoma. , 2022, Journal of Clinical Oncology.

[4]  P. Papageorgis,et al.  Evaluating Pancreatic and Biliary Neoplasms with Small Biopsy-Based Next Generation Sequencing (NGS): Doing More with Less , 2022, Cancers.

[5]  M. Schmelzle,et al.  Treatment of Intrahepatic Cholangiocarcinoma—A Multidisciplinary Approach , 2022, Cancers.

[6]  B. Teh,et al.  Cholangiocarcinoma , 2021, Nature Reviews Disease Primers.

[7]  Zeyu Zhang,et al.  A Bibliometric Analysis of 8,276 Publications During the Past 25 Years on Cholangiocarcinoma by Machine Learning , 2021, Frontiers in Oncology.

[8]  S. Truant,et al.  Liver Venous Deprivation or Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy? , 2021, Annals of surgery.

[9]  S. Truant,et al.  Liver Venous Deprivation or Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy? , 2021 .

[10]  W. Ryder,et al.  Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial , 2021, The Lancet. Oncology.

[11]  J. Qiu,et al.  Minimally invasive versus open radical resection surgery for hilar cholangiocarcinoma: Comparable outcomes associated with advantages of minimal invasiveness , 2021, PloS one.

[12]  G. Brandi,et al.  Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer , 2021, Expert opinion on investigational drugs.

[13]  J. Bridgewater,et al.  Targeting FGFR inhibition in cholangiocarcinoma. , 2021, Cancer treatment reviews.

[14]  G. Brandi,et al.  First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: "And Yet It Moves!" , 2021, Cancer treatment and research communications.

[15]  Yun Gao,et al.  Promising role of liver transplantation in patients with combined hepatocellular-cholangiocarcinoma: a propensity score matching analysis , 2021, Annals of Translational Medicine.

[16]  Juanyi Shi,et al.  Prognostic nomogram for predicting cancer-specific survival in patients with resected hilar cholangiocarcinoma: a large cohort study. , 2021, Journal of gastrointestinal oncology.

[17]  Z. Ren,et al.  Efficacy and safety of hepatic artery infusion chemotherapy with mFOLFOX in primary liver cancer patients with hyperbilirubinemia and ineffective drainage: a retrospective cohort study , 2021, Annals of Translational Medicine.

[18]  A. Zhu,et al.  Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. , 2020, The Lancet. Oncology.

[19]  E. Van Cutsem,et al.  Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. , 2020, The Lancet. Oncology.

[20]  S. Glaser,et al.  Cholangiocarcinoma: novel therapeutic targets , 2020, Expert opinion on therapeutic targets.

[21]  S. Knight,et al.  Identification of Circulating Genomic and Metabolic Biomarkers in Intrahepatic Cholangiocarcinoma , 2019, Cancers.

[22]  K. Zieniewicz,et al.  Surgery for cholangiocarcinoma , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[23]  J. Raftery,et al.  Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. , 2019, The Lancet. Oncology.

[24]  G. Brandi,et al.  Cholangiocarcinoma: Epidemiology and risk factors , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[25]  Kathryn J Fowler,et al.  Assessment and optimization of liver volume before major hepatic resection: Current guidelines and a narrative review. , 2018, International journal of surgery.

[26]  G. Gores,et al.  Cholangiocarcinoma — evolving concepts and therapeutic strategies , 2018, Nature Reviews Clinical Oncology.

[27]  P. Philip,et al.  Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  P. Lumbiganon,et al.  Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma , 2017 .

[29]  V. D’Andrea,et al.  The role of minimally invasive surgery in the treatment of cholangiocarcinoma. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[30]  Gad Getz,et al.  Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. , 2017, Cancer discovery.

[31]  T. Connelly,et al.  The 100 most influential manuscripts in colorectal cancer: A bibliometric analysis. , 2016, The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland.

[32]  A. Whittemore,et al.  Does radiotherapy still have a role in unresected biliary tract cancer? , 2016, Cancer medicine.

[33]  T. Pawlik,et al.  Is Radiotherapy Warranted Following Intrahepatic Cholangiocarcinoma Resection? The Impact of Surgical Margins and Lymph Node Status on Survival , 2016, Annals of Surgical Oncology.

[34]  W. Lewis,et al.  The 100 most influential manuscripts in gastric cancer: A bibliometric analysis. , 2016, International journal of surgery.

[35]  F. Couch,et al.  Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. , 2014, Human pathology.

[36]  T. Pawlik,et al.  A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience. , 2014, JAMA surgery.

[37]  Y. Totoki,et al.  Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma , 2014, Hepatology.

[38]  David M. Jones,et al.  New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. , 2014, The oncologist.

[39]  Eric W. Klee,et al.  Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma , 2014, PLoS genetics.

[40]  M. Nagino,et al.  Evolution of Surgical Treatment for Perihilar Cholangiocarcinoma: A Single-Center 34-Year Review of 574 Consecutive Resections , 2013, Annals of surgery.

[41]  M. Choti,et al.  Recurrence after operative management of intrahepatic cholangiocarcinoma. , 2013, Surgery.

[42]  Rameen Beroukhim,et al.  Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. , 2013, Gastroenterology.

[43]  S. Giulini,et al.  Surgical Approach for Long-term Survival of Patients With Intrahepatic Cholangiocarcinoma: A Multi-institutional Analysis of 434 Patients. , 2012, Archives of surgery.

[44]  Johnny C. Hong,et al.  Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. , 2012, Gastroenterology.

[45]  D. Seehofer,et al.  Oncological Superiority of Hilar En Bloc Resection for the Treatment of Hilar Cholangiocarcinoma , 2012, Annals of Surgical Oncology.

[46]  Myung Ah Lee,et al.  Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. , 2012, The Lancet. Oncology.

[47]  F. Giuliante,et al.  Improvement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients. , 2012, Archives of surgery.

[48]  M. Choti,et al.  Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  M. Grever,et al.  Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  T. Gruenberger,et al.  Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. , 2010, The Lancet. Oncology.

[51]  M. Nagino,et al.  Hepatectomy With Simultaneous Resection of the Portal Vein and Hepatic Artery for Advanced Perihilar Cholangiocarcinoma: An Audit of 50 Consecutive Cases , 2010, Annals of surgery.

[52]  D. Cunningham,et al.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. , 2010, The New England journal of medicine.

[53]  M. Highley,et al.  Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study – The UK ABC-01 Study , 2009, British Journal of Cancer.

[54]  J. Chung,et al.  The Prognosis and Survival Outcome of Intrahepatic Cholangiocarcinoma Following Surgical Resection: Association of Lymph Node Metastasis and Lymph Node Dissection with Survival , 2009, Annals of Surgical Oncology.

[55]  Yun Yen,et al.  A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer , 2009, Cancer Chemotherapy and Pharmacology.

[56]  Maria Hawkins,et al.  Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  A. Tannapfel,et al.  Surgical and Palliative Management and Outcome in 184 Patients With Hilar Cholangiocarcinoma: Palliative Photodynamic Therapy Plus Stenting Is Comparable to R1/R2 Resection , 2006, Annals of surgery.

[58]  Y. Sakamoto,et al.  One Hundred Two Consecutive Hepatobiliary Resections for Perihilar Cholangiocarcinoma With Zero Mortality , 2006, Annals of surgery.

[59]  M. Nagino,et al.  Two Hundred Forty Consecutive Portal Vein Embolizations Before Extended Hepatectomy for Biliary Cancer: Surgical Outcome and Long-term Follow-Up , 2006, Annals of surgery.

[60]  D. Apel,et al.  Palliation of Nonresectable Bile Duct Cancer: Improved Survival After Photodynamic Therapy , 2005, The American Journal of Gastroenterology.

[61]  G. Gores,et al.  Liver Transplantation with Neoadjuvant Chemoradiation is More Effective than Resection for Hilar Cholangiocarcinoma , 2005, Annals of surgery.

[62]  K. Hatakeyama,et al.  Impact of ductal resection margin status on long‐term survival in patients undergoing resection for extrahepatic cholangiocarcinoma , 2005, Cancer.

[63]  S. Okushiba,et al.  Forty Consecutive Resections of Hilar Cholangiocarcinoma With No Postoperative Mortality and No Positive Ductal Margins: Results of a Prospective Study , 2004, Annals of surgery.

[64]  T. Pawlik,et al.  Is Extended Hepatectomy for Hepatobiliary Malignancy Justified? , 2004, Annals of surgery.

[65]  J. Figueras,et al.  Spanish Experience in Liver Transplantation for Hilar and Peripheral Cholangiocarcinoma , 2004, Annals of surgery.

[66]  U. Mansmann,et al.  Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. , 2003, Gastroenterology.

[67]  M. D'Angelica,et al.  Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma , 2003, Cancer.

[68]  M. Makuuchi,et al.  Long-Term Outcome of Extended Hemihepatectomy for Hilar Bile Duct Cancer With No Mortality and High Survival Rate , 2003, Annals of surgery.

[69]  J. Vauthey,et al.  Preoperative Portal Vein Embolization for Extended Hepatectomy , 2003, Annals of surgery.

[70]  V. Vilgrain,et al.  Portal Vein Embolization Before Right Hepatectomy: Prospective Clinical Trial , 2003, Annals of surgery.

[71]  M. Miyazaki,et al.  Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival , 2002, The British journal of surgery.

[72]  M. Tempero,et al.  Radiochemotherapy and Transplantation Allow Long‐Term Survival For Nonresectable Hilar Cholangiocarcinoma , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[73]  Michael Flentje,et al.  Stereotactic Radiotherapy of Targets in the Lung and Liver , 2001, Strahlentherapie und Onkologie.

[74]  W. Jarnagin,et al.  Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. , 2001, Journal of the American College of Surgeons.

[75]  G. D. De Palma,et al.  Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: results of a prospective, randomized, and controlled study. , 2001, Gastrointestinal endoscopy.

[76]  M. Nagino,et al.  Lymph Node Metastasis from Hilar Cholangiocarcinoma: Audit of 110 Patients Who Underwent Regional and Paraaortic Node Dissection , 2001, Annals of surgery.

[77]  S. Kawasaki,et al.  Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma. , 2000, Surgery.

[78]  C. Meyer,et al.  Liver transplantation for cholangiocarcinoma: results in 207 patients. , 2000, Transplantation.

[79]  A. Tannapfel,et al.  Photodynamic therapy for advanced bile duct cancer: Evidence for improved palliation and extended survival , 2000, Hepatology.

[80]  W. Bechstein,et al.  Extended resections for hilar cholangiocarcinoma. , 1999, Annals of surgery.

[81]  G. Minoli,et al.  Photodynamic therapy of nonresectable cholangiocarcinoma , 1999 .

[82]  Randall G. Lee,et al.  Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. , 1998, Journal of the American College of Surgeons.

[83]  W. Jarnagin,et al.  Hilar Cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. , 1998, Annals of surgery.

[84]  C. Su,et al.  Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. , 1996, Annals of surgery.

[85]  A. Weaver,et al.  "Natural history" of unresected cholangiocarcinoma: patient outcome after noncurative intervention. , 1995, Mayo Clinic proceedings.

[86]  J. Donohue,et al.  Outcomes after curative resections of cholangiocarcinoma. , 1993, Archives of surgery.

[87]  P. Cotton,et al.  Palliation of proximal malignant biliary obstruction by endoscopic endoprosthesis insertion. , 1991, Gut.

[88]  S. Kondo,et al.  Combined portal vein and liver resection for carcinoma of the biliary tract , 1991, The British journal of surgery.

[89]  T. Pawlik,et al.  Intrahepatic cholangiocarcinoma: An international, multi-institutional analysis of prognostic factors and lymph node assessment. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  Randall G. Lee,et al.  Liver resection for hilar and peripheral cholangiocarcinomas: a study of 62 cases. , 1998, Annals of surgery.